Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Pinto Á, et al. Among authors: anido u. Clin Genitourin Cancer. 2022 Feb;20(1):25-34. doi: 10.1016/j.clgc.2021.09.006. Epub 2021 Oct 20. Clin Genitourin Cancer. 2022. PMID: 34789409
Zoledronic acid in genitourinary cancer.
Climent MA, Anido U, Méndez-Vidal MJ, Puente J. Climent MA, et al. Among authors: anido u. Clin Transl Oncol. 2013 Nov;15(11):871-8. doi: 10.1007/s12094-013-1033-1. Epub 2013 Apr 25. Clin Transl Oncol. 2013. PMID: 23615978 Review.
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J. García-Donas J, et al. Among authors: anido u. Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4. Lancet Oncol. 2017. PMID: 28389316 Free article. Clinical Trial.
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS. Bellmunt J, et al. Among authors: anido u. Ann Oncol. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186. Ann Oncol. 2017. PMID: 28419193 Free article. Clinical Trial.
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01).
García-Donas J, Leon LA, Esteban E, Vidal-Mendez MJ, Arranz JA, Garcia Del Muro X, Basterretxea L, González Del Alba A, Climent MA, Virizuela JA, Álvarez C, Sepúlveda J, Anido U, López C, Ortiz-Morales MJ, Pérez X, Rodriguez-Antona C, Rodriguez-Moreno JF, Hernando S, Castellano D. García-Donas J, et al. Among authors: anido u. Eur Urol Focus. 2017 Oct;3(4-5):430-436. doi: 10.1016/j.euf.2016.09.004. Epub 2016 Oct 4. Eur Urol Focus. 2017. PMID: 28753791
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D. Climent MÁ, et al. Among authors: anido u. Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2. Eur J Cancer. 2017. PMID: 29102858 Clinical Trial.
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Vázquez Estévez S, Anido U, Lázaro M, Fernández O, Fernández Núñez N, de Dios Álvarez N, Varela V, Campos Balea B, Agraso S, Areses MC, Iglesias L, Blanco M, Maciá S, Anton Aparicio LM. Vázquez Estévez S, et al. Among authors: anido u. Clin Transl Oncol. 2020 Sep;22(9):1565-1579. doi: 10.1007/s12094-020-02300-2. Epub 2020 Feb 15. Clin Transl Oncol. 2020. PMID: 32062835 Review.
38 results